Dynorphin B Activates Nuclear Opioid Receptors to Turn Stem Cells Into Heart Cells
Dynorphin B activated opioid receptors directly on the cell nucleus (not just the surface), triggering nuclear PKC signaling that activated cardiac transcription factors and promoted heart cell development from embryonic stem cells.
Quick Facts
What This Study Found
Dynorphin B activated nuclear opioid receptors coupling to nuclear PKC activation, which induced cardiac transcription factors (GATA-4, Nkx-2.5) for cardiogenesis in embryonic stem cells — a novel nuclear signaling mechanism.
Key Numbers
How They Did This
In-vitro study using embryonic stem cells. Nuclear opioid receptor activation by dynorphin B, nuclear PKC signaling, and cardiac gene expression measured with subcellular fractionation.
Why This Research Matters
Nuclear opioid receptors are a new signaling paradigm. If opioid peptides directly control gene expression through nuclear receptors, their effects are more fundamental and long-lasting than surface receptor signaling alone.
The Bigger Picture
Opioid signaling isn't just about fast cell-surface receptor events — it reaches into the nucleus to control gene programs. This adds a new dimension to understanding how opioid peptides regulate cell fate.
What This Study Doesn't Tell Us
In-vitro stem cell model. Nuclear opioid receptor signaling in mature cardiac tissue needs confirmation.
Questions This Raises
- ?Do nuclear opioid receptors function in adult heart cells?
- ?Could nuclear opioid signaling be therapeutically targeted?
- ?Does this mechanism explain opioid drugs' cardiac effects?
Trust & Context
- Key Stat:
- Nuclear opioid receptors Opioid signaling doesn't stop at the cell surface — dynorphin B activates receptors on the NUCLEUS to directly control cardiac gene programs
- Evidence Grade:
- Preliminary in-vitro evidence with novel subcellular signaling characterization in stem cells.
- Study Age:
- Published in 2003. Nuclear opioid receptor signaling has been further characterized as a distinct signaling modality.
- Original Title:
- Dynorphin B is an agonist of nuclear opioid receptors coupling nuclear protein kinase C activation to the transcription of cardiogenic genes in GTR1 embryonic stem cells.
- Published In:
- Circulation research, 92(6), 623-9 (2003)
- Authors:
- Ventura, Carlo(2), Zinellu, Elisabetta(2), Maninchedda, Emiliana(2), Maioli, Margherita
- Database ID:
- RPEP-00867
Evidence Hierarchy
Frequently Asked Questions
Can opioids signal inside the cell nucleus?
Yes — this study shows dynorphin B doesn't just activate surface receptors. It reaches opioid receptors on the nucleus itself, directly controlling gene expression for heart cell development.
Is this relevant to heart repair?
If opioid nuclear signaling promotes heart cell development from stem cells, it could be harnessed for cardiac regeneration. It adds a new tool to the regenerative medicine toolkit.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00867APA
Ventura, Carlo; Zinellu, Elisabetta; Maninchedda, Emiliana; Maioli, Margherita. (2003). Dynorphin B is an agonist of nuclear opioid receptors coupling nuclear protein kinase C activation to the transcription of cardiogenic genes in GTR1 embryonic stem cells.. Circulation research, 92(6), 623-9.
MLA
Ventura, Carlo, et al. "Dynorphin B is an agonist of nuclear opioid receptors coupling nuclear protein kinase C activation to the transcription of cardiogenic genes in GTR1 embryonic stem cells.." Circulation research, 2003.
RethinkPeptides
RethinkPeptides Research Database. "Dynorphin B is an agonist of nuclear opioid receptors coupli..." RPEP-00867. Retrieved from https://rethinkpeptides.com/research/ventura-2003-dynorphin-b-is-an
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.